Senolytic and anti-aging therapeutics market seen doubling by 2030

The Business Research Company projects rapid growth in the senolytic and anti-aging therapeutics market as aging populations, senescence research and preventive medicine drive demand. The market is forecast to rise from $2.18 billion in 2025 to $5.31 billion by 2030, with North America leading in 2025 and Asia-Pacific expected to grow fastest.

Why it matters: - The market is tied to therapies that target aging at the cellular level, which could reshape treatment for age-related disease and healthy-longevity care. - Strong forecast growth signals rising commercial interest in geroscience, preventive medicine and personalized treatment for older patients. - A larger elderly population is expanding the pool of potential patients worldwide.

What happened: - The Business Research Company released its Senolytic and Anti-Aging Therapeutics Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035 on July 22, 2026. - The report projects the market will grow from $2.18 billion in 2025 to $2.6 billion in 2026. - The report forecasts the market will reach about $5.31 billion by 2030. - The report says the market is growing at a 19.2% CAGR in the near term and 19.5% CAGR through 2030. - Download a free sample of the report. - View the full market report.

The details: - Senolytic and anti-aging therapeutics are designed to selectively remove senescent cells or slow biological aging. - The treatments aim to improve tissue function and extend healthy lifespan by reducing cellular damage and inflammation linked to aging. - Growth drivers cited in the report include age-related degenerative disease, limited success from traditional regenerative treatments, more funding for cellular senescence research, and the rise of early-stage longevity biotech companies. - The report points to technology advances that clear senescent cells, artificial intelligence in anti-aging drug discovery, personalized medicine for geriatric patients, preventive healthcare demand and clinical validation of senolytic therapies. - The report highlights geroscience-driven drug development, biomarkers for senescence, precision longevity treatments, preventive anti-aging care and combination therapies that blend senolytic and senomorphic approaches. - The World Health Organization said in February 2025 that the global population aged 60 and older is expected to rise from 1.1 billion in 2023 to 1.4 billion by 2030. - The report says North America held the largest market share in 2025. - The report says Asia-Pacific is expected to post the fastest growth during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The market outlook reflects a shift from aging research as a niche scientific field toward a more commercial drug-development category. - The emphasis on biomarkers, AI and combination therapies suggests the sector is moving from broad longevity claims toward more measurable and clinically testable approaches. - Regional growth patterns imply the U.S. and other established research markets may lead early adoption, while Asia-Pacific could become a faster expansion market as demand and healthcare investment broaden.

What's next: - The report expects continued momentum as more senolytic candidates move through clinical validation. - Developers will likely focus on senescence-clearing technologies, personalized longevity treatments and preventive care products. - Broader adoption will depend on whether the therapies can show clear clinical benefit in aging-related conditions. - The Business Research Company says its 2026 reports also include market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, hotspot infographics and updated graphics and tables.